Please use this identifier to cite or link to this item: http://hdl.handle.net/11189/8129
Title: Biochemical markers for identifying risk factors for disability progression in multiple sclerosis
Authors: Janse van Rensburg, S 
Kotze, Maritha J 
Cronje, Frans J. 
Davis, W 
Moremi, K 
Dashti, Jalali Sefid M 
Gamieldien, Junaid 
Geiger, D 
Rensburg, M 
Van Toorn, R. 
De Klerk, M.J. 
Hon, Gloudina Mary 
Matsha, Tandi Edith 
Hassan, Mogamat Shafick 
Erasmus, Rajiv T 
Keywords: Biochemical markers;risk factors;disability progression;multiple sclerosis;therapeutic strategies
Issue Date: 2013
Publisher: SASOP
Source: Janse van Rensburg, S., Kotze, M. J., Cronje, F. J. et al. 2013. Biochemical markers for identifying risk factors for disability progression in multiple sclerosis. (In: SASOP Biological Psychiatry Congress, Port Edward, 29 August-1 September 2013). [http://doi.org/10.4102/sajpsychiatry.v19i3.473]
Conference: SASOP Biological Psychiatry Congress, Port Edward, 29 August-1 September 2013 
Abstract: Background. Current therapeutic strategies for multiple sclerosis (MS), based on immune modulation, have modest efficacy in the prevention of disability. Objective. Pathology supported genetic testing (PSGT) was used to identify risk factors for disability progression and to guide personalised intervention to improve disease outcome in MS. Methods. Patients with MS (N=130) were assessed using lifestyle and diet questionnaires, as well as biochemical tests to identify markers for disability progression. Disability status was assessed using the Expanded Disability Status Scale (EDSS), ranging from 0 (no disability) to 10 (death due to MS). After following a personalised intervention programme that addressed the identified risk factors, patients were reassessed after 6 months, and again after 7 years. Results. At baseline, 30% of patients had non-anaemic iron deficiency, 65% had raised cholesterol values (>5.0 mmol/l), and 67% had high homocysteine levels. Vitamin D deficiency (<30 ng/ml) was found in 67% and vitamin D insufficiency (<50 ng/ml) in 81% of patients. In a pilot study with personalised intervention over 6 months, 12 compliant patients showed a significant improvement of 29.9% (the mean EDSS decreased from 3.50 to 2.45). After 7 years 12 compliant patients had a mean•}standard deviation (SD) EDSS of 1.4•}0.9. All of these patients scored ≤2.5, which is regarded as benign MS. Clinical improvement correlated with normalisation of blood parameters. Control subjects (n=12) who were not compliant, had a mean•}SD EDSS of 8.4•}1.5 after 7 years (difference significant, p<0.0001).
Description: Abstract
URI: http://hdl.handle.net/11189/8129
DOI: http://doi.org/10.4102/sajpsychiatry.v19i3.473
Appears in Collections:HWSci - Conference Papers

Files in This Item:
File Description SizeFormat 
Biochemical markers for identifying risk factors for disability progression in multiple.pdfAbstract312.84 kBAdobe PDFView/Open
Show full item record

Google ScholarTM

Check

Altmetric


Items in Digital Knowledge are protected by copyright, with all rights reserved, unless otherwise indicated.